Y Intercept Hong Kong Ltd Boosts Stock Position in NeoGenomics, Inc. $NEO

Y Intercept Hong Kong Ltd boosted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 67.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 139,809 shares of the medical research company’s stock after acquiring an additional 56,284 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in NeoGenomics were worth $1,037,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. First Horizon Corp increased its stake in shares of NeoGenomics by 52.6% during the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after purchasing an additional 865 shares in the last quarter. Headlands Technologies LLC purchased a new stake in NeoGenomics during the 2nd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of NeoGenomics by 110.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 1,556 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of NeoGenomics during the fourth quarter valued at approximately $39,000. Finally, GAMMA Investing LLC lifted its position in shares of NeoGenomics by 68.2% in the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 1,460 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director directly owned 91,422 shares in the company, valued at $1,032,154.38. The trade was a 5.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on NEO shares. William Blair reiterated a “market perform” rating on shares of NeoGenomics in a research report on Monday, March 16th. Weiss Ratings lowered shares of NeoGenomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Leerink Partners upgraded shares of NeoGenomics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Wall Street Zen raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Finally, Benchmark upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Wednesday, April 29th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NeoGenomics has an average rating of “Hold” and an average target price of $13.86.

NeoGenomics Trading Down 4.2%

NASDAQ:NEO traded down $0.62 during trading hours on Friday, hitting $14.11. The company had a trading volume of 1,377,877 shares, compared to its average volume of 3,692,974. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average of $11.08 and a 200 day moving average of $10.50. The company has a market cap of $1.84 billion, a P/E ratio of -18.32 and a beta of 1.74. NeoGenomics, Inc. has a 1 year low of $4.72 and a 1 year high of $15.57.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The business had revenue of $186.67 million for the quarter, compared to analyst estimates of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company’s quarterly revenue was up 11.3% on a year-over-year basis. Sell-side analysts expect that NeoGenomics, Inc. will post -0.15 earnings per share for the current year.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.